Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: CheckMate 032 Meeting Abstract
| Authors: | Ott, P. A.; Le, D. T.; Kim, J. W.; Ascierto, P. A.; Sharma, P.; Bono, P.; Peltola, K.; Jäger, D.; Evans, T. R. J.; de Braud, F.; Chau, I.; Bendell, J. C.; Tschaika, M.; Harbison, C. T.; Zhao, H.; Calvo, E.; Janjigian, Y. |
| Abstract Title: | Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: CheckMate 032 |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx369.058 |
| Language: | English |
| ACCESSION: | WOS:000411324001189 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx369.058 |
| Notes: | Meeting Abstract: 674P -- Appears on pages 229-230 of the abstract book -- Source: Wos |
